Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print

Latest Articles in biocon

Biocon Reports 71% Increase In Net Profit At Rs 144 Cr For June Quarter

The company had posted a net profit of Rs 84 crore in the April-June quarter of the previous fiscal

Read More

Biocon Eeceives 3 US FDA Observations On Its Telangana Plant

USFDA concluded a pre-approval inspection for Site 3 located at Hyderabad on July 2

Read More

Biocon To Buy 26% Stake In AMPYR Renewable Energy Resources Eleven

The company has entered into an agreement for the purpose of "acquisition of solar power by acquiring equity stake up to 26 per cent in AREREPL", it said

Read More

CCI Approves Serum Institute Life Sciences-Biocon Biologics Deal

Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to the notice filed with the regulator

Read More

Biocon's March Quarter Profit Falls 4% To Rs 283 Crore

Consolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period

Read More

Biocon Beefs Up Biosimilar Portfolio With $3.34 Bn Viatris Deal, Shares Fall

As per the deal, Viatris will get up to $2.34 billion in cash, and convertible shares in Biocon Biologics worth $1 billion

Read More

Biocon Biologics To Acquire Viatris Inc's Biosimilars Business for $3.33 Bn

The Board of Directors of both the companies have approved the transaction and the deal is expected to close in the second half of the year

Read More

Shares Of Biocon Surge Over 2% On Strong December Qtr Numbers

On the BSE, the stock opened at Rs 363.00, then jumped 2.61 per cent and touched an early high of Rs 373.40 in initial deals. It was later trading at Rs 371.25, up 2.02 per cent.

Read More

USFDA Rejects Biocon, Viatris Application For Insulin Aspart

The USFDA has issued a complete response letter (CRL) for the biologics licence application (BLA) for Insulin Aspart filed by our partner Viatris (Mylan),

Read More

Biocon In Talks With Mylan To Merge Biosimilar Businesses: Report

Spokespersons for Biocon and Viatris Inc, the company which was formed after combining Mylan with Pfizer Inc's off-patent branded drugs business, said that the companies do not comment on market rumours and speculation.

Read More

USFDA Issues 6 Observations After Inspection Of Biocon's Malaysian Arm Mfng Facility

At the conclusion of the inspection, the agency has issued a Form 483 with a total of 6 observations across Drug Substance, Drug Product and Devices Facilities

Read More

Sebi Bars Allegro Capital, Individual For Insider Trading Activities In Biocon Shares

Allegro Capital and its director as well as major shareholder Kunal Ashok Kashyap have been fined Rs 10 lakh each, according to an order by Sebi dated July 8.

Read More

Insider Trading Case: Sebi Bars Biocon's Official From Securities Mkt For 3 Months, Levies Fine

Biocon had announced information relating to its collaboration with Sandoz and the period of unpublished price sensitive information (UPSI) was from December 20, 2017 to January 18, 2018

Read More

Sebi Fines Biocon, Its Designated Person For Violating Mkt Norms

Market norms require that violation of code of conduct (CoC) be informed to the regulator 'promptly.' Biocon informed Sebi after 28 days of becoming aware of violation of company's code of conduct.

Read More

Biocon Case: Sebi Bans 6 Entities For 2 Yrs For Manipulative Trades

The regulator has directed these four entities to disgorge the unlawful gains made by them along with an interest of 12 per cent per annum.

Read More